Published in PLoS One on July 30, 2014
Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians. PLoS One (2015) 0.79
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice. Endocrinol Metab (Seoul) (2017) 0.77
Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke. Alzheimers Dement (Amst) (2016) 0.76
Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimers Dement (Amst) (2017) 0.75
Clusterin: full-length protein and one of its chains show opposing effects on cellular lipid accumulation. Sci Rep (2017) 0.75
Apolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease? Chin Med J (Engl) (2015) 0.75
Upregulation of Early and Downregulation of Terminal Pathway Complement Genes in Subcutaneous Adipose Tissue and Adipocytes in Acquired Obesity. Front Immunol (2017) 0.75
A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism. Alzheimers Res Ther (2017) 0.75
Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) (2017) 0.75
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Inflammation and metabolic disorders. Nature (2006) 33.33
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Inflammatory links between obesity and metabolic disease. J Clin Invest (2011) 6.73
Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology (2003) 4.28
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) (2006) 3.03
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab (2007) 2.58
Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry (2009) 2.57
Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol (1995) 1.73
Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol (2008) 1.55
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem (1991) 1.44
Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res (2006) 1.40
Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care (1998) 1.39
Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation (2003) 1.33
The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord (2003) 1.30
Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry (1994) 1.24
Macrophages, meta-inflammation, and immuno-metabolism. ScientificWorldJournal (2011) 1.10
Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol (2002) 1.09
Alzheimer disease: Insulin resistance and AD--extending the translational path. Nat Rev Neurol (2012) 1.03
Chapter 8: Clusterin: A multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res (2009) 1.03
Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol (2009) 0.97
Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb (2006) 0.92
Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest (1994) 0.91
Identification of the disulfide bonds in human plasma protein SP-40,40 (apolipoprotein-J). J Biochem (1992) 0.91
Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care (1999) 0.87
Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis (2001) 0.86
Hepatic apolipoprotein J is secreted as a lipoprotein. J Lipid Res (1992) 0.86
Genetic variation in clusterin gene and Alzheimer's disease risk in Han Chinese. Neurobiol Aging (2013) 0.85
Effect of obesity on plasma clusterin, [corrected] a proposed modulator of leptin action. Pediatr Res (2011) 0.81
Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler Thromb (2009) 0.79
Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer? Electrophoresis (2012) 0.78